Enter multiple symbols separated by commas

Teva Pharmaceutical Industries Ltd


  • Mylan, whose shares fell 14.5 percent, said it would continue its own unsolicited pursuit of Irish drugmaker Perrigo Co, a maker of over-the-counter consumer and nutritional products and generic topical medicines. Perrigo is one of the few remaining assets out there, "said Morningstar analyst Michael Waterhouse. Other industry analysts expect Mylan will...

  • NEW YORK, July 27- Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger. As head of Actavis, he then sealed a $66 billion purchase of Botox-maker Allergan, beating out rival suitor Valeant...

  • Teva and Restaurant Brands are big market movers Monday, 27 Jul 2015 | 4:25 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:. Teva Pharmaceuticals Industries Ltd., up $10.15 to $72. Restaurant Brands International Inc., up $1.41 to $41.50.

  • The Dutch drugmaker Mylan, which had resisted Teva's advances for three months, is pressing ahead with its offer for Irish drug and ingredients maker Perrigo. Perrigo has turned down Mylan's offer. If they can't work it out, Perrigo might find other suitors as the competitive generic drug industry keeps consolidating.

  • Early movers: AGN, MYL, MHFI, UBS, FCAU & more Monday, 27 Jul 2015 | 7:48 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • TEL AVIV, July 27- Teva Pharmaceutical Industries has agreed to buy Allergan Plc's generic drugs business for $40.5 billion in a cash and stock deal that will turn the Israeli company into one of the world's largest pharmaceutical firms. It also will allow Dublin- based Allergan, the third-largest generic drugmaker in the United States, to focus on branded drugs...

  • Teva to buy Allergan's generics business for $40.5B Monday, 27 Jul 2015 | 7:38 AM ET
    A clinical technician holds a syringe and a vial of Allergan Botox, produced by Allergan.

    Allergan chief Brent Saunders says the sale of its generics business would allow the company to double down on its higher margin branded business.

  • TEL AVIV, July 27- Teva Pharmaceutical Industries has agreed to buy Allergan Plc's generic drugs business for $40.5 billion in a deal that will turn Teva into one of the top 10 pharmaceutical companies. Allergan's generic business is generally seen as a better fit than Teva's previous target Mylan because it will improve Teva's distribution channels and...

  • JERUSALEM— Israel's Teva Pharmaceutical Industries Ltd. said Monday it is purchasing Dublin- based Allergan PLC's generic pharmaceuticals business for $40.5 billion, in what Israeli analysts called the largest-ever acquisition by an Israeli company. Statements from both companies say the deal will see Allergan receive $33.75 billion in cash and shares...

  • Allergan to acquire Naurex as Teva talks continue Sunday, 26 Jul 2015 | 3:18 PM ET

    Allergan PLC, the Dublin- based pharmaceutical giant, announced Sunday it has agreed to buy Naurex, a developer of drugs for depression and other central nervous system disorders, for $560 million. The announcement comes among reports that Allergan is in talks to sell its enormous generic drug division to Israel- based Teva Pharmaceutical Industries Ltd. The...

  • Allergan buys Naurex for $560M as deal talk swirls Sunday, 26 Jul 2015 | 11:20 AM ET
    A clinical technician holds a syringe and a vial of Allergan Botox, produced by Allergan.

    Allergan is considering a breakup of the company into two businesses, a person familiar with the matter told Reuters on Friday.

  • Teva closes in on Allergan’s generics unit Sunday, 26 Jul 2015 | 5:45 AM ET
    An employee collects newly-manufactured pills at Teva Pharmaceutical Industries headquarters in Jerusalem, Israel.

    Teva Pharmaceutical is nearing a deal to acquire Allergan's generics drug unit for between $40bn and $45bn, according to people familiar with the matter. The FT reports.

  • July 25- Teva Pharmaceutical Industries Ltd is in advanced talks to buy Allergan Plc's generic drug business following a thus far unsuccessful effort to acquire peer Mylan NV, according to a person familiar with the matter. Jerusalem- based Teva, which has offered to buy Mylan for $40 billion, is now close to an agreement to acquire Dublin- based Allergan's...

  • July 25- Israeli drug maker Teva Pharmaceutical Industries Ltd is in talks to combine with Allergan Plc's big generic-drug business, the Wall Street Journal reported on Saturday, citing people familiar with the matter. A deal for the Allergan business, valued at about $45 billion, could be announced as early as Monday, one of the people said, according to the...

  • Mylan puts up barrier to Teva with Dutch legal maneuver Thursday, 23 Jul 2015 | 1:31 PM ET

    Mylan wants to combine its generic drugs with Perrigo Co.' s over-the-counter medicines, generic drugs, nutritional products and infant formulas. Mylan says that's too low, and its wants to go ahead with a previous offer to buy Perrigo, an Irish company that makes over-the-counter medicines and other products. Mylan's valued its latest offer for Perrigo at...

  • Is there a conflict of interest at Supreme Court? Tuesday, 21 Jul 2015 | 1:02 PM ET
    U.S. Supreme Court Chief Justice John Roberts, from left, stands with fellow justices Anthony Kennedy, Ruth Bader Ginsburg, Stephen Breyer and Elena Kagan.

    Rulings by justices with a potential financial interest in the outcome of the cases raise new questions about the credibility of the court.

  • WASHINGTON, July 14- A proposed merger of the two largest U.S. generic drug makers drew fire on Tuesday from Consumers Union and seven other groups, who asked antitrust enforcers to stop Teva Pharmaceutical Industries Ltd's proposal to purchase Mylan NV, saying it would lead to higher prices and more drug shortages. Meanwhile, Mylan has pressed on with a $34...

  • TEL AVIV, July 8- As Israel's biggest company Teva strives to get even bigger by swallowing up rival Mylan for more than $40 billion, further down the food chain a raft of upstart life science firms are struggling to climb onto the global ladder. Israel has a burgeoning life science industry comprising around 1,380 mostly very small companies.

  • Your first trade for Wednesday Tuesday, 7 Jul 2015 | 6:14 PM ET

    The "Fast Money" traders give their final trades of the day.

  • M&A close to record in Q2 amid mega deals Tuesday, 30 Jun 2015 | 6:54 AM ET

    Mergers and acquisitions worldwide in the second quarter of 2015 almost matched the record set in the second quarter of 2007.